Other groups developed and characterized 99mTc-labeled BBN-folate conjugates (99mTc-BBN-folate) aiming at combining the targeting capabilities of BBN, directed toward GRPR, and folate, which targets folate receptors (such as FRα) commonly overexpressed in breast cancer cells. Here, GRPR is linked to breast carcinoma.